Mangoceuticals (MGRX) Stock Rockets 130% Following CEO’s Substantial Share Award

Key Highlights

• Shares of MGRX skyrocketed more than 129% during Monday’s trading following SEC disclosure of a 500,000-share bonus awarded to CEO Jacob Cohen.
• An additional 200,000 shares were transferred by Cohen to The Tiger Cub Trust, an entity under his control, increasing the trust’s holdings to 805,000 shares.
• Daily trading volume exploded to over 107 million shares, vastly exceeding the three-month average of approximately 208,000.
• Despite Monday’s surge, the stock declined 54.51% in Friday’s session and remains down 78.11% for the year.
• Analyst consensus remains at “Strong Sell” with no current price target coverage from major firms.

---

Shares of Mangoceuticals (MGRX) experienced a dramatic surge exceeding 129% during Monday’s trading session following the disclosure of regulatory filings showing CEO Jacob Cohen was granted 500,000 shares as bonus compensation.

Mangoceuticals, Inc., MGRX

In the same filing, Cohen relocated 200,000 shares into The Tiger Cub Trust, which operates under his direction, pushing the trust’s aggregate position to 805,000 shares. The simultaneous disclosure of both equity movements ignited significant market attention.

The rally represents a sharp reversal from Friday’s trading, when shares plummeted 54.51%. Year-to-date performance shows MGRX down 78.11%, while the 12-month decline stands at 96.59%.

Trading activity on Monday was extraordinary, with transaction volume surpassing 107 million shares—a massive increase compared to the typical three-month daily average of roughly 208,000 shares.

According to MarketBeat records, the most recent closing price stood at approximately $2.33 per share as of late October 2025. Currently, no active analyst price targets are available for the stock.

Legal Action and Intellectual Property Initiatives

Beyond executive compensation disclosures, Mangoceuticals has been active on multiple strategic fronts. The company announced it initiated litigation against Clarity Ventures, Inc., its former technology partner, pursuing damages in excess of $73 million. The legal action alleges breaches related to technology service delivery and platform development obligations.

Regarding intellectual property expansion, the company submitted a PCT international patent application in February for MGX-0024, described as an antiviral additive technology designed for incorporation into animal feed and water systems. The February 26, 2026 filing aims to secure worldwide patent protection.

Operational Highlights

The company’s $99 monthly injectable testosterone replacement therapy (TRT) subscription service has demonstrated strong performance. Company executives reported 336% month-over-month revenue growth beginning in mid-December, accompanied by a 54% reduction in customer acquisition expenses.

Mangoceuticals additionally launched MangoRx Direct and PeachesRx Direct in November 2025. These direct-to-consumer platforms offer access to GLP-1 weight management medications including Zepbound and Wegovy, with monthly pricing beginning around $499 on a cash-pay model.

However, despite operational developments, Wall Street coverage remains limited and unfavorable. MarketBeat data shows one Sell rating with no Buy or Hold recommendations currently assigned to the stock.

The overall analyst consensus stands at “Strong Sell,” with no major investment firms having issued upgrades, downgrades, or fresh price objectives in recent months.

The latest available closing price on record stands at roughly $2.33 per share from late October 2025.

The post Mangoceuticals (MGRX) Stock Rockets 130% Following CEO’s Substantial Share Award appeared first on Blockonomi.